In this cohort study of 10 660 patients with cirrhosis who were receiving furosemide and spironolactone, use of SGLT-2 inhibitors was associated with a significantly reduced risk of serious liver events compared with diuretic therapy alone. Here, SLC5A2 is linked to Cirrhosis.